Saratov JOURNAL of Medical and Scientific Research

Modern approaches to treatment of uveitis in systemic diseases of connective tissue

Year: 2018, volume 14 Issue: №4 Pages: 956-960
Heading: Ophtalmology Article type: Review
Authors: Kamalova K.B., Zakirkhodjayev R.A., Asrorkhodjayeva I.R.
Organization: Tashkent Medical Academy

 Uveitis can develop in various systemic diseases of connective tissue. This article provides data on modern methods of treatment for such cases of uveitis. Uveitis in systemic diseases of the connective tissue develops due to violations of cellular and humoral immunity. Given the pathogenesis of the primary disorder, treatment of uveitis in systemic diseases of connective tissue involves use of cytotoxic drugs, TNFa inhibitors, cytokines, antibodies to lymphocyte surface antigens, and immunoglobulins. Due to the chronic course of the disorder and frequent relapses, it is advisable to use local and systemic glucocorticoid drugs with prolonged effect. The combined corticosteroid drug diprospan containing the two active ingredients of betamethasone provides a combination of immediate and prolonged effects, thereby improving patient's clinical condition and prolonging the period of remission.

1 Zierhut M, Kotter I, Lorenz H. Problems associated with treating ocular disease in underlying inflammatory rheumatic disease. Z Rheumatology 2010; 69 (5): 393-6
2 DubininaTV, DeminaAB, ErdesShF. HLA-B27-associated uveitis: epidemiology, clinical presentation and complications. Scientific practical rheumatology 2014; 304-8
3 TrunovAN, Arbeneva NS, ShvayukAP. Cytokine imbalance in the tear fluid of patients with autoimmune uveitis. Vestnik Orenburskogo gosudarstvennogo universiteta 2013; (4): 270-4
4 Fayzieva DB. The role of humoral immunity factors and inflammatory markers in the pathogenesis of rheumatoid etiology uveitis. Theoretical and clinical medicine journal 2015; (4): 130-3. (Uzbekistan)
5 Wechsler В, Sable-Fourtassou R., Bodaghi В. Infliximab in refractory uveitis due to Behchet diseas. J Clin Exp Rheum 2004; (34): 1416
6 Godzenko AA, Razumova lYu, Bochkova AG. Clinical evaluation of uveitis and its importance in the diagnosis of spondyloarthritis. Scientific-practical rheumatology 2011; (6): 38-42
7 Razumova lYu. A prospective study of uveitis in spondyloarthritis and their association with the histocompatibility antigen HLA-B27. Vestnik oftalmologii 2016; 132 (4): 4-9
8 Kamilov НМ, Fayzieva DB. Markers of inflammation and humoral factors of immunity in patients with rheumatoid uveitis. Journal of theoretical and clinical medicine 2013; (6): 110-3. (Uzbekistan)
9 Fayzieva DB, Kamilov НМ. Differentiated treatment of endogenous uveitis. Medical Journal of Uzbekistan 2013; (4): 8-10. (Uzbekistan)
10 Malkhanov VB, Marvanova ZR, Zaynutdinova GKh. Prediction of the clinical course of inflammatory eye diseases: Method. Recommendations. Ufa, 2008; p. 20
11 Godzenko AA. Prospects for the treatment of uveitis in rheumatic diseases. Modern rheumatology 2011; (3): 3-7
12 Katargina LA, Arkhipova LT Uveitis: pathogenetic immunosuppressive therapy. M., 2004; 100 p.
13 Munos-Femandes S, Hidalgo V, Fernandes-Melon J. Sulfasalasine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatology 2003; 30 (6): 1277-9
14 Fayzieva DB, Kamilov HM. Immunotherapy in various forms of endogenous uveitis. Journal of theoretical and clinical medicine 2013; (5): 134-7. (Uzbekistan)
15 Yadav UC, Kaiarya NM, Ramana KV. Emerging role of antioxidants in the protection of uveitis complications. Current Medical Chemistry 2011; 18 (6): 931-42
16 Maracheva NM, Panova IE, Grafova TV. The clinical efficacy of the drug Mexidol in the complex treatment of acute post-traumatic uveitis and its effect on local hemodynamics in patients with penetrating wounds of the eyeball. Russian Ophthalmological Journal 2012; 5 (1): 51-6
17 Drozdova ЕА. Uveitis in rheumatic diseases: clinical features, diagnosis, immunopathogenesis and treatment. Moscow, 2010
18 Chesnokova NB, Neroev VV, Beznos OV, et al. Influence of instillations of dexamethasone and superoxidase on the course of uveitis and local biochemical processes. Vestnik oftalmologii 2015; 131 (3): 71-4
19 Bikbov MM, Shevchuk NE, Malkhanov VB. Cytokines in clinical ophthalmology. Ufa, 2008; 154 p.
21 Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumathology 2005; 44(8): 1008-11
22 Teplinskaya LE, Filichkina NS, Matevosova KS. The effectiveness of the treatment of uveitis with "Superlymph". Vestnik oftalmologii 2015; (4): 22-6
24 Ohno S, Nakamura S, Hori S. Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behchet diseas with refractory uveoretinitis. Rheumatology 2004; 31 (7): 1362-8
25 Razumova lYu, Godzenko AA. HLA-B27-associated uveitis. Vestnik oftalmologii 2009; (4): 46-50
26 Katsnelson LA, Tankovsky VE. Uveits (clinic, treatment). Moscow, 2013; 286 p.
27 Moiseenko ОМ, Balabin OV The effectiveness of diprospan in the treatment of uveitis. New in ophthalmology 2003; (2): 32-3.

2018_4-2_956-960.pdf274.46 KB

No votes yet